The Antitumor Activity of a Novel Fluorobenzamidine against Dimethylhydrazine-Induced Colorectal Cancer in Rats.
Colorectal cancer is among the leading causes of death worldwide. The incidence of deaths is projected to be 11.4 million in 2030. We aimed to evaluate the in vitro and in vivo antioxidant and antitumor activities of a novel bithiophene-fluorobenzamidine (BFB) against DMH-induced colorectal cancer in rats. The antiproliferative activity of BFB against HCT-116 colon cancer cells and apoptotic genes was assessed. In vivo study was also launched, 80 adult male rats were divided into 5 groups; control, BFB, and the other 3 groups were injected with DMH (20mg/kg, s.c., for 9 weeks). Then group 4 was injected with 5 doses of cisplatin (2.5mg/kg, i.p over 21 weeks) and group 5 was injected with 3 doses/week of BFB (2.5mg/kg, i.p, for 21 weeks). BFB has weak to moderate in vitro antioxidant activity. BFB had a strong antiproliferative activity with IC50 at ~0.3µg/ml. BFB induced extrinsic apoptosis through upregulation of FasL, TRAL, p53 and caspase-8, and intrinsic apoptosis through downregulation of Bcl-2 and surviving. BFB decreased the tumor incidence, multiplicity and size and improved the decreased body weight. BFB also ameliorated the kidney and liver functions and antioxidants deteriorated by DMH. BFB significantly improved the pathological changes caused by DMH in colon tissues. BFB showed a very promising antitumor activity against colorectal cancer induced by DMH in rats without causing hepato- or nephro-toxicity.